Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$90.78
-0.9%
$89.57
$52.50
$99.50
$1.97B0.58371,071 shs264,284 shs
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$25.46
+4.0%
$13.43
$5.90
$26.99
$2.73B2.374.48 million shs9.90 million shs
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$11.94
+0.3%
$12.28
$5.78
$13.85
$2.08B1.452.02 million shs3.74 million shs
Organogenesis stock logo
ORGO
Organogenesis
$4.04
-2.2%
$4.67
$2.61
$6.71
$512.51M1.681.33 million shs511,738 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-0.03%+1.63%-3.73%+38.65%+61.38%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
+19.72%+30.44%+106.67%+101.23%+36.78%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
+3.39%+7.88%-6.29%+7.49%+27.79%
Organogenesis stock logo
ORGO
Organogenesis
-0.24%-2.59%-13.42%-6.14%+38.13%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$90.78
-0.9%
$89.57
$52.50
$99.50
$1.97B0.58371,071 shs264,284 shs
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$25.46
+4.0%
$13.43
$5.90
$26.99
$2.73B2.374.48 million shs9.90 million shs
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$11.94
+0.3%
$12.28
$5.78
$13.85
$2.08B1.452.02 million shs3.74 million shs
Organogenesis stock logo
ORGO
Organogenesis
$4.04
-2.2%
$4.67
$2.61
$6.71
$512.51M1.681.33 million shs511,738 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-0.03%+1.63%-3.73%+38.65%+61.38%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
+19.72%+30.44%+106.67%+101.23%+36.78%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
+3.39%+7.88%-6.29%+7.49%+27.79%
Organogenesis stock logo
ORGO
Organogenesis
-0.24%-2.59%-13.42%-6.14%+38.13%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
2.90
Moderate Buy$99.1410.08% Upside
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
2.52
Moderate Buy$27.9511.33% Upside
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
2.75
Moderate Buy$22.6389.09% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.25
Hold$7.3383.56% Upside

Current Analyst Ratings Breakdown

Latest ORGO, NTLA, OCUL, and ANIP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/9/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$77.00 ➝ $90.00
10/8/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$15.00 ➝ $19.00
10/8/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C-)Sell (D+)
10/8/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Organogenesis stock logo
ORGO
Organogenesis
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/6/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket PerformOutperform$33.00
10/6/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket PerformMarket Outperform$33.00
10/3/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$21.00 ➝ $31.00
10/3/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$17.00 ➝ $24.00
10/2/2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$747.40M2.61$7.46 per share12.07$19.11 per share4.71
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$57.88M46.56N/AN/A$8.56 per share2.93
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
$63.72M32.67N/AN/A$2.01 per share5.95
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.05$0.20 per share19.84$2.09 per share1.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-$18.52M-$0.77N/A21.39N/A-1.37%25.03%8.00%11/14/2025 (Estimated)
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$519.02M-$4.69N/AN/AN/A-908.48%-57.48%-45.04%11/6/2025 (Estimated)
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$193.51M-$1.28N/AN/AN/A-382.51%-71.92%-49.36%11/13/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.14N/AN/AN/A-1.92%-0.37%-0.20%11/6/2025 (Estimated)

Latest ORGO, NTLA, OCUL, and ANIP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$1.00N/AN/AN/AN/AN/A
11/6/2025Q3 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.07N/AN/AN/A$134.10 millionN/A
8/8/2025Q2 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.42$1.80+$0.38$0.36$187.18 million$211.37 million
8/7/2025Q2 2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$1.03-$0.99+$0.04-$0.98$12.26 million$14.25 million
8/7/2025Q2 2025
Organogenesis stock logo
ORGO
Organogenesis
-$0.01-$0.09-$0.08-$0.10$104.75 million$101.01 million
8/5/2025Q2 2025
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
-$0.35-$0.39-$0.04-$0.39$13.12 million$13.46 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
N/AN/AN/AN/AN/A
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/AN/AN/AN/AN/A
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
1.39
2.54
1.96
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/A
5.19
5.19
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
0.23
10.10
10.02
Organogenesis stock logo
ORGO
Organogenesis
N/A
3.95
3.45

Institutional Ownership

CompanyInstitutional Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
76.05%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
88.77%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
59.21%
Organogenesis stock logo
ORGO
Organogenesis
49.57%

Insider Ownership

CompanyInsider Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
11.10%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
3.10%
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
2.30%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
60021.70 million19.29 millionOptionable
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
600107.35 million104.02 millionOptionable
Ocular Therapeutix, Inc. stock logo
OCUL
Ocular Therapeutix
230173.99 million169.99 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.86 million85.00 millionOptionable

Recent News About These Companies

Organogenesis (NASDAQ:ORGO) Receives "Buy" Rating from BTIG Research
Why Is Organogenesis Stock Trading Lower Friday?
Organogenesis Provides Update on Second Phase 3 ReNu® Study
Organogenesis Provides Update on Second Phase 3 ReNu® Study
Organogenesis: Transformational Changes Taking Shape

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANI Pharmaceuticals stock logo

ANI Pharmaceuticals NASDAQ:ANIP

$90.78 -0.87 (-0.95%)
Closing price 04:00 PM Eastern
Extended Trading
$93.50 +2.72 (+3.00%)
As of 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Intellia Therapeutics stock logo

Intellia Therapeutics NASDAQ:NTLA

$25.46 +0.99 (+4.05%)
Closing price 04:00 PM Eastern
Extended Trading
$25.60 +0.14 (+0.55%)
As of 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Ocular Therapeutix stock logo

Ocular Therapeutix NASDAQ:OCUL

$11.94 +0.03 (+0.25%)
Closing price 04:00 PM Eastern
Extended Trading
$11.93 -0.01 (-0.08%)
As of 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.04 -0.09 (-2.18%)
Closing price 04:00 PM Eastern
Extended Trading
$3.98 -0.06 (-1.61%)
As of 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.